Cambridge Investment Research Advisors Inc. Sells 182 Shares of Balchem Co. (NASDAQ:BCPC)

Cambridge Investment Research Advisors Inc. reduced its stake in shares of Balchem Co. (NASDAQ:BCPC – Get Rating) by 2.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,837 shares of the basic materials company’s stock after selling 182 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Balchem were worth $957,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of BCPC. TCI Wealth Advisors Inc. boosted its holdings in Balchem by 261.3% in the 3rd quarter. TCI Wealth Advisors Inc. now owns 271 shares of the basic materials company’s stock worth $33,000 after buying an additional 196 shares during the period. Quantbot Technologies LP bought a new position in Balchem in the 1st quarter worth approximately $34,000. Point72 Hong Kong Ltd bought a new position in Balchem in the 1st quarter worth approximately $67,000. Focused Wealth Management Inc boosted its holdings in Balchem by 3,881.3% in the 4th quarter. Focused Wealth Management Inc now owns 637 shares of the basic materials company’s stock worth $78,000 after buying an additional 621 shares during the period. Finally, Quadrant Capital Group LLC boosted its holdings in Balchem by 532.5% in the 3rd quarter. Quadrant Capital Group LLC now owns 993 shares of the basic materials company’s stock worth $121,000 after buying an additional 836 shares during the period. 89.29% of the stock is owned by institutional investors.

Balchem Stock Performance

NASDAQ BCPC opened at $124.17 on Friday. Balchem Co. has a 1 year low of $110.15 and a 1 year high of $143.88. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.88 and a quick ratio of 1.81. The stock has a market capitalization of $4.00 billion, a PE ratio of 40.58 and a beta of 0.70. The company’s 50 day simple moving average is $126.47 and its two-hundred day simple moving average is $129.87.

Balchem (NASDAQ:BCPC – Get Rating) last posted its earnings results on Friday, April 28th. The basic materials company reported $0.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by ($0.08). Balchem had a return on equity of 10.69% and a net margin of 10.48%. The firm had revenue of $232.54 million during the quarter, compared to analysts’ expectations of $232.00 million. During the same quarter in the prior year, the company earned $0.89 earnings per share. Analysts predict that Balchem Co. will post 3.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. StockNews.com assumed coverage on shares of Balchem in a report on Thursday. They issued a “hold” rating for the company. HC Wainwright lowered their target price on shares of Balchem from $152.00 to $140.00 in a research note on Monday, February 27th.

Insiders Place Their Bets

In other news, SVP Michael Robert Sestrick sold 2,300 shares of the firm’s stock in a transaction on Tuesday, May 2nd. The shares were sold at an average price of $130.36, for a total transaction of $299,828.00. Following the sale, the senior vice president now owns 5,424 shares in the company, valued at approximately $707,072.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, SVP Michael Robert Sestrick sold 2,300 shares of the firm’s stock in a transaction on Tuesday, May 2nd. The shares were sold at an average price of $130.36, for a total transaction of $299,828.00. Following the sale, the senior vice president now owns 5,424 shares in the company, valued at approximately $707,072.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David B. Fischer sold 3,000 shares of the firm’s stock in a transaction on Monday, March 20th. The shares were sold at an average price of $127.01, for a total transaction of $381,030.00. Following the sale, the director now owns 17,269 shares in the company, valued at approximately $2,193,335.69. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Balchem Company Profile

(Get Rating)

Balchem Corp. provides marketing of specialty performance ingredients and products. It operates through the following segments: Human Nutrition and Health, Animal Nutrition and Health, Specialty Products and Industrial Products. The Human Nutrition and Health segment supplies ingredients in the food and beverage industry, providing customized solutions in powder, solid and liquid flavor delivery systems, spray dried emulsified powder systems, and cereal systems.